☰

Jonathan R. Hart, Ph.D. - Publications

Affiliations: 
California Institute of Technology, Pasadena, CA 
Area:
application of transition metal complexes to probe recognition and reactions of double helical DNA
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Raffeiner P, Hart JR, García-Caballero D, Bar-Peled L, Weinberg MS, Vogt PK. An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation. Proceedings of the National Academy of Sciences of the United States of America. PMID 32156728 DOI: 10.1073/Pnas.1921786117  0.391
2019 Bell CM, Raffeiner P, Hart JR, Vogt PK. Cooperates with to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9. Cancers. 11. PMID 31652979 DOI: 10.3390/Cancers11111634  0.397
2018 Ito Y, Hart JR, Vogt PK. Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets. Expert Opinion On Therapeutic Targets. PMID 30205700 DOI: 10.1080/14728222.2018.1522302  0.36
2018 Jacob NT, Miranda PO, Shirey RJ, Gautam R, Zhou B, de Orbe Izquierdo ME, Hixon MS, Hart JR, Ueno L, Vogt PK, Janda KD. Synthetic molecules for disruption of the MYC protein-protein interface. Bioorganic & Medicinal Chemistry. PMID 30037753 DOI: 10.1016/J.Bmc.2018.07.019  0.343
2017 Ito Y, Vogt PK, Hart JR. Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β. Oncotarget. 8: 55863-55876. PMID 28915558 DOI: 10.18632/Oncotarget.19866  0.326
2017 Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, Farina NH, Lian JB, Tomasello L, Liu CG, Palamarchuk A, Hart JR, Bell C, Carosi M, Pescarmona E, et al. tsRNA signatures in cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 28696308 DOI: 10.1073/Pnas.1706908114  0.37
2016 Vogt PK, Hart JR, Yates JR. A butterfly effect in cancer. Molecular & Cellular Oncology. 3: e1029063. PMID 27308543 DOI: 10.1080/23723556.2015.1029063  0.316
2016 Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell. 165: 643-655. PMID 27104980 DOI: 10.1016/J.Cell.2016.03.045  0.308
2015 Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV, Weinberg MS. Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26581162 DOI: 10.1038/Mt.2015.202  0.31
2015 Vadie N, Saayman S, Lenox A, Ackley A, Clemson M, Burdach J, Hart J, Vogt PK, Morris KV. MYCNOS functions as an antisense RNA regulating MYCN. Rna Biology. 12: 893-9. PMID 26156430 DOI: 10.1080/15476286.2015.1063773  0.339
2015 Hart JR, Zhang Y, Liao L, Ueno L, Du L, Jonkers M, Yates JR, Vogt PK. The butterfly effect in cancer: a single base mutation can remodel the cell. Proceedings of the National Academy of Sciences of the United States of America. 112: 1131-6. PMID 25583473 DOI: 10.1073/Pnas.1424012112  0.376
2015 Hart JR, Bister K, Janda KD, Vogt PK. Abstract A23: Identification of KJ-Pyr-9 as a potent MYC inhibitor Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A23  0.406
2015 Hart JR, Zhang Y, Liao L, Du L, Yates JR, Vogt PK. Abstract A28: Butterfly effect in cancer: How a PI3-kinase mutation remodels the cell Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A28  0.402
2015 Hart JR, Bister K, Janda KD, Vogt PK. Abstract 965: Identification of KJ-Pyr-9 as a potent MYC inhibitor Cancer Research. 75: 965-965. DOI: 10.1158/1538-7445.Am2015-965  0.407
2014 Hart JR, Roberts TC, Weinberg MS, Morris KV, Vogt PK. MYC regulates the non-coding transcriptome. Oncotarget. 5: 12543-54. PMID 25587025 DOI: 10.18632/Oncotarget.3033  0.333
2014 Ito Y, Hart JR, Ueno L, Vogt PK. Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K). Proceedings of the National Academy of Sciences of the United States of America. 111: 16826-9. PMID 25385636 DOI: 10.1073/Pnas.1420281111  0.373
2014 Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget. 5: 8869-78. PMID 25326649 DOI: 10.18632/Oncotarget.2588  0.396
2014 Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee JK, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library. Proceedings of the National Academy of Sciences of the United States of America. 111: 12556-61. PMID 25114221 DOI: 10.1073/Pnas.1319488111  0.395
2014 Hart JR, Zhang Y, Liao L, Du L, Yates JR, Vogt PK. Abstract 5249: Butterfly effect in cancer: How a single base mutation of PIK3CA remodels multiple pathways Cancer Research. 74: 5249-5249. DOI: 10.1158/1538-7445.Am2014-5249  0.407
2014 Ito Y, Hart JR, Ueno L, Vogt PK. Abstract 3339: The regulatory subunit of PI3K, p85β, induces cellular transformation, enhanced cell proliferation and increased PI3K signaling Cancer Research. 74: 3339-3339. DOI: 10.1158/1538-7445.Am2014-3339  0.4
2011 Vogt PK, Hart JR. PI3K and STAT3: a new alliance. Cancer Discovery. 1: 481-6. PMID 22348200 DOI: 10.1158/2159-8290.Cd-11-0218  0.378
2011 Sun M, Hart JR, Hillmann P, Gymnopoulos M, Vogt PK. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (Georgetown, Tex.). 10: 3731-9. PMID 22045127 DOI: 10.4161/Cc.10.21.17920  0.334
2011 Hart JR, Liao L, Yates JR, Vogt PK. Essential role of Stat3 in PI3K-induced oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America. 108: 13247-52. PMID 21788516 DOI: 10.1073/Pnas.1110486108  0.369
2011 Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget. 2: 467-76. PMID 21670491 DOI: 10.18632/Oncotarget.293  0.364
2011 Hart JR, Liao L, Ueno L, Yates JR, Vogt PK. Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle (Georgetown, Tex.). 10: 971-6. PMID 21350335 DOI: 10.4161/Cc.10.6.15077  0.373
2010 Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proceedings of the National Academy of Sciences of the United States of America. 107: 15547-52. PMID 20713702 DOI: 10.1073/Pnas.1009652107  0.387
2010 Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A. Phosphatidylinositol 3-kinase: the oncoprotein. Current Topics in Microbiology and Immunology. 347: 79-104. PMID 20582532 DOI: 10.1007/82_2010_80  0.402
2010 Dannemann N, Hart JR, Ueno L, Vogt PK. Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. International Journal of Cancer. Journal International Du Cancer. 127: 239-44. PMID 19876913 DOI: 10.1002/Ijc.25012  0.392
2009 Vogt PK, Hart JR. Akt demoted in glioblastoma. Science Signaling. 2: pe26. PMID 19383977 DOI: 10.1126/Scisignal.267Pe26  0.362
2009 Vogt PK, Gymnopoulos M, Hart JR. PI 3-kinase and cancer: changing accents. Current Opinion in Genetics & Development. 19: 12-7. PMID 19185485 DOI: 10.1016/J.Gde.2008.11.011  0.338
2008 Denley A, Gymnopoulos M, Hart JR, Jiang H, Zhao L, Vogt PK. Biochemical and biological characterization of tumor-associated mutations of p110alpha. Methods in Enzymology. 438: 291-305. PMID 18413256 DOI: 10.1016/S0076-6879(07)38020-8  0.365
2006 Hart JR, Glebov O, Ernst RJ, Kirsch IR, Barton JK. DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators. Proceedings of the National Academy of Sciences of the United States of America. 103: 15359-63. PMID 17030786 DOI: 10.1073/Pnas.0607576103  0.515
2004 Hart JR, Johnson MD, Barton JK. Single-nucleotide polymorphism discovery by targeted DNA photocleavage. Proceedings of the National Academy of Sciences of the United States of America. 101: 14040-4. PMID 15383659 DOI: 10.1073/Pnas.0406169101  0.432
2004 Rüba E, Hart JR, Barton JK. [Ru(bpy)2(L)]Cl2: luminescent metal complexes that bind DNA base mismatches. Inorganic Chemistry. 43: 4570-8. PMID 15257584 DOI: 10.1021/Ic0499291  0.456
2003 Junicke H, Hart JR, Kisko J, Glebov O, Kirsch IR, Barton JK. A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition. Proceedings of the National Academy of Sciences of the United States of America. 100: 3737-42. PMID 12610209 DOI: 10.1073/Pnas.0537194100  0.472
Show low-probability matches.